Copenhagen-based Enduro Genetics has successfully secured €12 million in a Series A funding round. This investment underscores the growing interest in innovative solutions that enhance efficiency and reduce costs in large-scale biological production. 

About Enduro Genetics

Denmark based Enduro Genetics is a leader in biotechnology companies that intend to change the face of the world of biomanufacturing. The business focuses on highly reducing the large-scale biological costs by using the new method for “addiction” of cells to high production. This assures the cells do not lose optimal productivity, ensuring increased overall efficiency in manufacturing.

Enduro Genetics focuses on developing robust microbial strains that are engineered to sustain high levels of production over extended periods. By integrating advanced genetic engineering techniques with a deep understanding of cellular metabolism, the company creates solutions that are both innovative and practical for industrial applications.

Founders and Leadership

Enduro Genetics was co-founded by Peter Rugbjerg and Christian Mundigo.

Peter Rugbjerg: He is the Chief Scientific Officer and has extensive experience in microbial physiology and metabolic engineering. His research interests are in understanding and optimizing cellular processes to improve production efficiency in biomanufacturing.

Christian Mundigo: As the Chief Technology Officer, Mundigo specializes in synthetic biology and genetic engineering. His work involves designing and constructing genetic circuits that enhance microbial production capabilities.

In April 2023, the company appointed Christian Munch as the new Chief Executive Officer. Munch’s leadership is expected to drive the company’s strategic initiatives and accelerate its growth trajectory.

Funding Details

The €12 million Series A funding round was led by Supernova Invest, NOON Ventures, and Sandwater. This investment brings Enduro Genetics’ total funding to €18 million, including previous grants from the BioInnovation Institute and the European Innovation Council accelerator. 

The newly acquired capital will be utilized to expand the company’s technology platform and expedite the commercialization of its innovative solutions.

Strategic Objectives Post-Funding

With the infusion of new capital, Enduro Genetics aims to:

• Enhance Technology Platform: Invest in the development of advanced genetic tools and methodologies to improve the efficiency and scalability of their microbial strains.
• Accelerate Commercialization: Fast-track the deployment of their solutions in industrial settings, establishing partnerships with key players in the biomanufacturing sector.
• Expand Research and Development: Broaden their R&D efforts to explore new applications of their technology in various industries, including pharmaceuticals, agriculture, and biofuels.
• Scale Production Capabilities: Increase their production capacity to meet the growing demand for cost-effective and efficient biomanufacturing solutions.

The Innovative Approach: “Addicting” Cells to High Production

Enduro Genetics’ core innovation lies in its unique method of “addicting” cells to high production. This process involves genetically modifying microbial cells to create a dependency on the production of a desired compound for their survival. As a result, the cells are “addicted” to producing the target molecule, ensuring sustained high-level production.

This approach addresses common challenges in biomanufacturing, such as the decline in productivity over time due to cellular stress or metabolic burden. By making the production process essential for cell survival, Enduro’s method maintains consistent output, thereby reducing costs and increasing efficiency in large-scale production.

Market Context and Future Outlook

The biomanufacturing industry is poised for significant growth, driven by the increasing demand for sustainable and efficient production methods across various sectors. 

Enduro Genetics’ innovative approach positions the company to capitalize on this trend by offering solutions that not only enhance productivity but also reduce operational costs.

With the new funding, Enduro Genetics is well-equipped to scale its operations and make a substantial impact on the biomanufacturing landscape. The company’s focus on innovation and efficiency aligns with the industry’s move towards more sustainable and cost-effective production methods.

Source: Enduro